Europe: CJEU rules on SPC term

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Europe: CJEU rules on SPC term

In Estonia a patent was granted on April 15 1998 followed by a marketing authorisation on June 8 2001 for a pharmaceutical composition comprising the active agent capecitabine. Based thereon a supplementary protection certificate (SPC) was requested and granted. According to Estonian national SPC regulations the SPC provided a protection term of 15 years from the date of grant of the marketing authorization, that is until June 8 2016.

On December 15 2014, however, a generic competitor wanted to bring a generic composition comprising capecitabine onto the Estonian market since, according to the competitor´s calculation, the SPC protection term ended on June 10 2013. The patentee filed an infringement suit against the competitor and the court of second instance, the Tallinn Court of Appeal, transferred the case to the CJEU for clarification of the termination date of the SPC in Estonia.

How did the discrepancy in the calculation of the termination dates arise?

On May 1 2004 Estonia became a member of the EU and according to European SPC regulations the protection term of an SPC is calculated based on the first marketing authorisation in the EU which, in the present case, was granted for capecitabine in Switzerland on June 10 1998. The CJEU hinted that Article 21(2) of SPC Regulation 469/2009 states that the regulation applies to SPCs granted according to national regulations in Estonia prior to the date of Estonia´s accession to the EU.

Further, Article 13 of this regulation in conjunction with recital 9 thereof indicates that the holder of both the patent and the SPC should not be able to enjoy more than 15 years of exclusivity from the time of the first marketing authorisation granted in the EU which, according to Article 13, has to be interpreted as the European Economic Area (EEA). Accordingly, the protection term of an SPC is calculated based on the first marketing authorisation in the EEA, even if a national SPC was granted based on a national marketing authorisation before accession of the country in question to the EU.

hermann.jpg

Bettina Hermann


V.O.Johan de Wittlaan 72517 JR The HagueThe NetherlandsTel: +31 70 416 67 11Fax: +31 70 416 67 99info@vo.euwww.vo.eu

more from across site and SHARED ros bottom lb

More from across our site

AG Barr acquires drinks makers Fentimans and Frobishers, in deals worth more than £50m in total
Tarun Khurana at Khurana & Khurana says corporates must take the lead if patent filing activity is to truly translate into innovation
Michael Moore, head of legal at Glean AI, discusses how in-house IP teams can use AI while protecting enforceability
Counsel for SEP owners and implementers are keeping an eye on the case, which could help shape patent enforcement strategy for years to come
Jacob Schroeder explains how he and his team secured victory for Promptu in a long-running patent infringement battle with Comcast
After Matthew McConaughey registered trademarks to protect his voice and likeness against AI use, lawyers at Skadden explore the options available for celebrities keen to protect their image
The Via members, represented by Licks Attorneys, target the Chinese company and three local outfits, adding to Brazil’s emergence as a key SEP litigation venue
The firm, which has revealed profits of £990,837, claims it is the disruptive force in the IP-legal industry
In the first of a two-parter, lawyers at Santarelli analyse the patentability of therapeutic inventions where publication of clinical trial protocols occurs before the application's filing date
Arun Hill at Clarivate assesses the Top 100 Global Innovators 2026 list, including why AI has assumed a strategic importance for innovation
Gift this article